12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GALNS: Extension study preliminary data

BioMarin reported preliminary data from patients with MPS-IVA who have reached 36 and 48 weeks of total treatment time with GALNS in the double-blind, international Phase III MOR-005 extension study of the double-blind, international Phase III MOR-004 trial in 176 patients. Patients receiving once-weekly 2 mg/kg IV GALNS had mean increases in 6-minute walk distance (6MWD) from baseline of 46.6 meters at week 36 (n=27) and 45.4 meters at week 48 (n=13). Patients receiving 2 mg/kg GALNS given every other week had mean increases in...

Read the full 401 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >